A pilot study: (131)I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

The purpose of this study was to determine the feasibility and assess the efficacy and toxicity, among newly diagnosed malignant glioma patients, of administering (131)I-labeled murine antitenascin monoclonal antibody 81C6 ((131)I-81C6) into a surgically created resection cavity (SCRC) to achieve a...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Reardon, David A., Zalutsky, Michael R., Akabani, Gamal, Coleman, R. Edward, Friedman, Allan H., Herndon, James E., McLendon, Roger E., Pegram, Charles N., Quinn, Jennifer A., Rich, Jeremy N., Vredenburgh, James J., Desjardins, Annick, Guruangan, Sridharan, Boulton, Susan, Raynor, Renee H., Dowell, Jeanette M., Wong, Terence Z., Zhao, Xiao-Guang, Friedman, Henry S., Bigner, Darell D.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Duke University Press 2008
Ämnen:
Clinical Investigations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2613820/
https://ncbi.nlm.nih.gov/pubmed/18287339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2007-053
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk